Logo

Cardinal Health Reports the Discontinuation of Biosimilar Infliximab & Switched Back to Remicade in the VA Study for Inflammatory Conditions

Share this

Cardinal Health Reports the Discontinuation of Biosimilar Infliximab & Switched Back to Remicade in the VA Study for Inflammatory Conditions

Shots:

  • The US Veterans Healthcare Administration study helps to determine the patients who tried an infliximab biosimilar after being treated with Remicade & were switched to another innovator biologic in patients with RA, PsA, PsO, AS, CD & UC
  • Of the 653 patients who switched off the biosimilar to another innovator biologic, 594 switched back to Remicade. The results were similar with Remicade & with RA and IBD & showed a median duration of follow-up of 796 & 337 days who switched to a biosimilar & continued to the reference infliximab
  • Additionally, the results also showed that the patients who switched to the biosimilar had no increase in disease activity

Ref: Center for Biosimilars  | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions